» Articles » PMID: 11737582

Autosomal-dominant Hypophosphatemic Rickets (ADHR) Mutations Stabilize FGF-23

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2001 Dec 12
PMID 11737582
Citations 196
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The gene for the renal phosphate wasting disorder autosomal-dominant hypophosphatemic rickets (ADHR) is FGF23, which encodes a secreted protein related to the fibroblast growth factors (FGFs). We previously detected missense mutations R176Q, R179W, and R179Q in FGF23 from ADHR kindreds. The mutations replace R residues within a subtilisin-like proprotein convertase (SPC) cleavage site 176RHTR-179 (RXXR motif). The goal of these studies was to determine if the ADHR mutations lead to protease resistance of FGF-23.

Methods: The ADHR mutations were introduced into human FGF-23 cDNA clones with or without an N-terminal FLAG tag by site-directed mutagenesis and were transiently transfected into HEK293 cells. Protein expression was determined by Western analyses.

Results: Antibodies directed toward the C-terminal portion of FGF-23 revealed that the native FGF-23 protein resolved as 32 kD and 12 kD species in HEK293 conditioned media; however, the three mutated proteins were detected only as the 32 kD band. An N-terminal FLAG-tagged native FGF-23 resolved as two bands of 36 kD and 26 kD when detected with a FLAG antibody, whereas the R176Q mutant resolved primarily as the 36 kD protein species. Cleavage of FGF-23 was not enhanced by extracellular incubation of FGF-23 with HEK293 cells. Native and mutant FGF-23s bound heparin.

Conclusions: FGF-23 proteins containing the ADHR mutations are secreted, and produce polypeptides less sensitive to protease cleavage than wild-type FGF-23. Therefore, the ADHR mutations may protect FGF-23 from proteolysis, thereby potentially elevating circulating concentrations of FGF-23 and leading to phosphate wasting in ADHR patients.

Citing Articles

Hypophosphatemia in pregnancy: A case report.

Dogra P, Bhavna B, Kaundal A, Malik N, Kaushal S Niger Med J. 2025; 65(6):1156-1159.

PMID: 39877493 PMC: 11770657. DOI: 10.60787/nmj.v65i6.603.


Skeletal abnormalities caused by a Connexin43 mutation in a mouse model for autosomal recessive craniometaphyseal dysplasia.

Fujii Y, Okabe I, Hatori A, Sah S, Kanaujiya J, Fisher M Bone Res. 2025; 13(1):14.

PMID: 39848944 PMC: 11757998. DOI: 10.1038/s41413-024-00383-z.


Exploring endocrine FGFs - structures, functions and biomedical applications.

Phan P, Ternier G, Edirisinghe O, Kumar T Int J Biochem Mol Biol. 2024; 15(4):68-99.

PMID: 39309613 PMC: 11411148. DOI: 10.62347/PALK2137.


Inherited phosphate and pyrophosphate disorders: New insights and novel therapies changing the oral health landscape.

Foster B, Boyce A, Millan J, Kramer K, Ferreira C, Somerman M J Am Dent Assoc. 2024; 155(11):912-925.

PMID: 39127957 PMC: 11540754. DOI: 10.1016/j.adaj.2024.05.016.


Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance.

Marin A, Morales F, Walbaum B Front Oncol. 2024; 14:1406951.

PMID: 39040443 PMC: 11260626. DOI: 10.3389/fonc.2024.1406951.